ArticleFrontiers in oncology2025
Exceptional responses to Trastuzumab deruxtecan in HER2-positive breast cancer: two illustrative case reports.
Zelmira Ballatore et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it